A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics

SK Quinney1,2, AN Mohamed3, MF Hebert1,5, DM Haas1,2, S Clark4, JG Umans7,8, SN Caritis9 and L Li10; for the Obstetric-fetal Pharmacology Research Unit Network

Physiological changes in pregnancy, including changes in body composition and metabolic enzyme activity, can alter drug pharmacokinetics. A semi-mechanistic metabolism model was developed to describe the pharmacokinetics of two cytochrome P450 3A (CYP3A) substrates, midazolam and nifedipine, in obstetrical patients. The model parameters were optimized to fit the data of oral midazolam pharmacokinetics in pregnant women, by increasing CYP3A-induced hepatic metabolism 1.6-fold in the model with no change in gut wall metabolism. Fetal metabolism had a negligible effect on maternal plasma drug concentrations. Validation of the model was performed by applying changes in volume of distribution and metabolism, consistent with those observed for midazolam, to the pharmacokinetics parameters of immediate-release nifedipine in healthy volunteers. The predicted steady-state areas under the concentration–time curve (AUCs) for nifedipine were within 15% of the data observed in pregnant women undergoing treatment for preterm labor. This model predicts the pharmacokinetics of two CYP3A substrates in pregnancy, and may be applicable to other CYP3A substrates as well.

We have proposed a semi-mechanistic pharmacokinetic model of drug metabolism, based on standard one- or two-compartment models and incorporating both hepatic and intestinal metabolism. This approach uses compartmental pharmacokinetic parameters available from the literature or derived from clinical study data. Metabolic enzyme activity can be estimated from in vitro rate constants or from clinical data. This model has been validated for the cytochrome P450 3A (CYP3A) probe substrate, midazolam, using data from drug–drug interaction studies with ketoconazole, clarithromycin, diltiazem, and erythromycin in healthy volunteers.

Here, we adapt this semi-mechanistic model to describe drug disposition in pregnancy, incorporating placental and fetal compartments and physiologic changes associated with pregnancy (Figure 1 and Table 1). The parameters of the model are optimized using midazolam clinical pharmacokinetic data in pregnancy; sensitivity analyses are performed to illustrate the impact of fetal metabolism, changes in hepatic blood flow, plasma protein binding, and CYP3A activity on plasma midazolam concentrations. Based on the adjusted parameter estimates determined for midazolam, the model was used for predicting the concentration levels of another CYP3A substrate, nifedipine, in pregnant women.
were 17.4 and 16.9 ng·h/ml, respectively.

All other parameters as in Quinney et al.

Table 1 Model parameter values

| Parameter | Midazolam, healthy* | Midazolam, pregnant* | Nifedipine, healthy* | Nifedipine, pregnant* |
|-----------|---------------------|----------------------|---------------------|----------------------|
| Vc (l)    | 43 (28%)            | 45.9 (28%)           | 20 (28%)            | 23 (28%)             |
| Vp (l)    | 88.4 (20%)          | 93.9 (20%)           | 30 (20%)            | 35.5 (20%)           |
| kₐ (h⁻¹) | 1.17 (40%)          | 2.5 (40%)            | 3.36 (40%)          | 4.48 (40%)           |
| f                         | 0.04                | 0.048                | 0.05                | 0.06                |
| Vmax,u(mg/h)              | 2.755 (30%)         | 4.592 (30%)          | 1.245 (30%)         | 1.992 (30%)          |
| Vmax,gw(mg/h)             | 2.549 (30%)         | 2.549 (30%)          | 1.245 (30%)         | 1.245 (30%)          |
| Kₚ (µmol/l)              | 5.8                 | 5.8                  | 5.0                 | 5.0                 |
| Vmax,fet (µmol/l)         | 0.65                | 0.65                 |                      |                      |
| Vmaxplac (µmol/l)         | 3.4                 | 3.4                  |                      |                      |
| Vmax,MGW (µmol/h)         | 88                  | 167                  |                      |                      |
| Km,MGW (µmol/l)           | 114                 | 34                   |                      |                      |
| Qp (l/h)                 | 10.8                | 10.8                 |                      |                      |
| Qs (l/h)                 | 15.9                | 15.9                 |                      |                      |

All other parameters as in Quinney et al. and provided in supplementary information online.

*Data presented as mean (%CV).

**RESULTS**

Postpartum midazolam model

The healthy volunteer model for midazolam was used to simulate plasma midazolam concentrations after a 2-mg oral dose of the drug. Predicted plasma midazolam concentrations were similar to those observed in women 6–10 weeks postpartum (Figure 2a). Observed and predicted areas under the concentration–time curve (AUCs) from time 0 to ∞ (AUC∞) were 17.4 and 16.9 ng·h/ml, respectively (residual sum of squares, 20.8; percentage error, 3%).

Midazolam obstetric model

The initial semi-mechanistic obstetrics model for midazolam metabolism was based on the model derived from data in healthy human volunteers, with the addition of placental and fetal compartments (Figure 1), a 20% increase in fraction unbound (fₚ), a twofold increase in intestinal and hepatic CYP3A clearance (Vmax), and an increased volume of distribution (Vd) based on reports in the literature. In comparison with observed midazolam data at 28–32 weeks' gestation, the model underestimated (AUC∞) (5.7 vs. 9.5 ng·h/ml) and maximal plasma concentration (Cmax) (2.1 vs. 6.4 ng/ml) (Figure 2b and Table 2).

Sensitivity analyses

In order to identify the impact of individual parameters on the midazolam concentration–time curve, select parameter values were varied 0.5- and 2-fold relative to the initial model (Figure 3 and Table 2). Changes in hepatic blood flow (Qh) and the absorption rate constant (kₐ) had little effect on AUC, but a large effect on Cmax. A twofold change in fₚ had large effects on the plasma concentration–time curve. Similarly, reducing Vmax,gw or Vmax,h increased both the AUC and the Cmax of midazolam.

The contribution of the fetus to maternal drug pharmacokinetics was also examined using sensitivity analysis. Fetal hepatic Vmax was estimated to be 88 mg/h, based on in vitro CYP3A7 metabolism of midazolam and estimated expression of CYP3A7 in the fetal liver. Completely excluding fetal clearance (Vmax,fet = 0) did not alter the maternal concentration–time course of midazolam. Even increasing the Vmax,gw by as much as 20-fold reduced midazolam AUC in maternal plasma only minimally (Table 1). Although fetal metabolism has little effect on maternal plasma drug concentration, it may impact fetal exposure. However, given the low intrinsic clearance of midazolam by the fetal liver, even a complete exclusion of fetal metabolism is predicted to increase fetal (AUC∞) of midazolam by only 2%. Additionally, changes in fetal blood flow (Qf) and Qmax did not significantly affect plasma concentrations (see Supplementary Figure S1 online). It therefore appears likely that the effect of fetal metabolism on maternal plasma midazolam concentration is minimal.

The volume of distribution of midazolam is expected to be higher in pregnancy because of increased plasma volume, increased extracellular volume, and decreased binding. We assumed that in pregnancy, the increase in the central volume of distribution is proportional to the change in plasma volume, and that peripheral volume of distribution accounts for additional increases in the total volume of distribution. Sensitivity analysis indicates that the maternal plasma drug concentration–time profile was not sensitive to changes in the volume of the peripheral compartment (see Supplementary Figure S2 online).

The original model, which anticipated that the effects of pregnancy on CYP3A Vmax would be similar in the gut wall and the liver, led to underestimation of Cmax. Based on results of the sensitivity analysis and iterative model fitting, the initial model of midazolam disposition in pregnancy was revised such that kₚ was increased to 2.5 h⁻¹, Vmax,gw was increased 1.6-fold, and Vmax,fet was left unchanged from the healthy volunteer model. This modified pregnancy model was able to accurately predict midazolam AUC within 1%, but continued to underestimate Cmax by 23% (Figure 2c).
Application to nifedipine

In order to validate the increased hepatic CYP3A activity associated with pregnancy, we applied our model to another CYP3A substrate, nifedipine. Using data from the literature, we constructed a model of nifedipine pharmacokinetics in healthy volunteers (Table 1).\textsuperscript{15,16} The two-compartment parameters and \textit{in vitro} metabolism kinetics adequately predicted the pharmacokinetics of oral nifedipine (10 mg) in healthy volunteers (Figure 4a). The mean predicted AUC\textsubscript{0–8} of nifedipine, 156 ng·h/ml (95% confidence interval of 149–163), was similar to the mean observed AUC\textsubscript{0–8}, 180 ng·h/ml (95% confidence interval of 150–210). Parameter adjustments were made as in the midazolam model (Table 1), and the steady-state concentration of nifedipine after oral administration of a 20 mg immediate-release capsule every 6 h was predicted in pregnant subjects (Figure 4b). As compared to observed data in subjects taking nifedipine for preterm labor,\textsuperscript{17} the median AUC\textsubscript{0–6} was underpredicted by 11% (210 (121–299) ng·h/ml vs. 237 (224–253) ng·h/ml), and \textit{C}_{\text{max}} was underpredicted by 3% (178 (166–188) ng/ml vs. 184 (90–308) ng/ml).

DISCUSSION

Pharmacokinetic studies of the CYP3A substrates, midazolam and nifedipine, have recently been conducted in pregnant women (25–34 weeks of gestation).\textsuperscript{10,17} Both drugs are predominately metabolized by CYP3A, the intrinsic clearance (CL\textsubscript{int}) showing CYP3A4 > CYP3A5 > CYP3A7.\textsuperscript{13} Unlike many other CYP3A substrates, neither drug is significantly transported by p-glycoprotein.\textsuperscript{18,19} Clinical studies\textsuperscript{10,11} indicate that CYP3A activity increases in pregnancy. By incorporating various physiologic changes of pregnancy into a pharmacokinetic model, we attempted to isolate the effect of pregnancy on CYP3A activity. PBPK models have long been used to estimate fetal toxicity.\textsuperscript{5} However, relatively few models have been developed to estimate the pharmacokinetics of therapeutic drugs in pregnancy.
The primary purpose of this model is to estimate changes in drug clearance and maternal pharmacokinetics of drugs. We have simplified the model to focus on important organs of drug metabolism, namely, intestine and liver. Although not impacting the pharmacokinetics of these CYP3A substrates, placental aromatase and (perhaps) fetal hepatic enzymes may play a role in the metabolism of other drugs (e.g., methadone as a substrate of CYP19). Therefore, we believe that separation of fetal and placental compartments may be relevant in the case of some drugs. This is similar to models proposed by Gabrielson and Paalzow.5 We have additionally collapsed the PBPK model into two compartments: peripheral distribution and central distribution. This is in contrast to PBPK models proposed by Gaohua et al. and Andrews et al., which propose 13 and 20 maternal compartments, respectively.20,21 While our model may not fully describe pregnancy-related changes in drug distribution, this simplification allows us to focus on the roles of the relevant organs during this initial stage of model development.

Model development
The original semi-mechanistic drug metabolism model was developed based on midazolam pharmacokinetics in healthy volunteers taking part in drug–drug interaction studies.7–9 The healthy volunteer model incorporated the key organs involved in the absorption, metabolism, and distribution of oral drugs: intestinal lumen, intestinal wall, liver, portal circulation, and systemic circulation. Other physiologic compartments, which are not key determinants of drug clearance, were collapsed into the central and peripheral compartments. Compartments associated with drug metabolism are assumed to be part of the fast-equilibrating compartment, and their volumes are therefore deducted from that of the central compartment.

Sensitivity analysis
Intestinal absorption of drugs may be affected in pregnancy by alterations in gastric motility and pH.22 Being a high-permeability drug, midazolam is nearly completely absorbed from the gastrointestinal tract. However, changes in motility can impact the rate of intestinal absorption (i.e., $k_a$), altering both $C_{\text{max}}$ and time to reach $C_{\text{max}}$ ($t_{\text{max}}$). Sensitivity analyses

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Sensitivity analysis of obstetric semi-mechanistic metabolism model. The solid line indicates predicted maternal plasma drug concentration based on the initial obstetric semi-mechanistic metabolism model. Broken and dotted lines represent twofold decreases and increases, respectively, in (a) hepatic blood flow, $Q_H$; (b) absorption rate constant, $k_a$; (c) fraction unbound, $f_u$; (d) intestinal rate of metabolism, $V_{\text{max}}$; (e) hepatic rate of metabolism, $V_{\text{max},H}$; and (f) effect of fetal metabolism on maternal plasma concentrations as predicted by the initial model (solid line), assuming no contribution from fetal metabolism (dotted line), and with a 20-fold increase in cytochrome P450 3A7 (CYP3A7) $V_{\text{max}}$ (dashed line).}
\end{figure}
indicated that increasing the $k_e$ of midazolam improved prediction by the obstetric model (Figure 3b).

There are some data, though limited, to suggest that pregnancy has little effect on hepatic blood flow. In addition, the sensitivity analysis results suggested that changes in hepatic blood flow would have little effect on the AUC of oral midazolam (Figure 3a). Therefore, it does not appear that changes in hepatic blood flow are responsible for the increased clearance of midazolam during pregnancy.

Midazolam is highly bound to albumin, and therefore even small changes in protein binding are capable of producing marked changes in the drug’s systemic clearance. This is shown in the sensitivity analysis, where a decrease in $f_a$ from 0.048 to 0.024 has an effect on midazolam pharmacokinetics similar to that resulting from a twofold increase in hepatic $V_{\text{max}}$ (Figure 3 and Table 2). In pregnancy, albumin concentrations decrease by ~20%, with average albumin concentrations in the third trimester being $38.8 \pm 2.9$ g/l as compared to $47.7 \pm 2.5$ g/l in nonpregnant women. Consequently, the protein binding of drugs that bind primarily to albumin, such as midazolam and nifedipine, is expected to decrease, leading to increased clearance. However, the effect of protein binding cannot fully account for the twofold increase in clearance observed in pregnant women.

Given that changes in liver blood flow and protein binding do not completely account for increased midazolam clearance, it is possible that altered metabolism, either in the liver or fetal/placental unit, may play a role. The presence of CYP3A activity in the placenta is still a matter of debate. CYP3A4, CYP3A5, and CYP3A7 mRNA have been identified in preterm placenta, but the amounts are much lower than those found in the liver.

However, only one study has observed CYP3A activity in placenta. It is unknown whether other placental enzymes (e.g., CYP19) are capable of midazolam metabolism. Because of the incompleteness of current knowledge, we did not consider placenta as a potential driver of midazolam clearance in our model. Fetal liver expresses CYP3A7 to a greater extent than CYP3A4 or CYP3A5. In vitro studies of midazolam with CYP3A isoforms, and knowledge of CYP3A7 expression in the fetal liver, provided the data for estimating the contribution of the fetal liver to midazolam disposition. As shown in Figure 3f, metabolism of midazolam in the fetal liver had a negligible effect on maternal plasma midazolam concentrations.

Consequently, it appears that the increased midazolam clearance in pregnancy is largely caused by increased hepatic CYP3A activity. Interestingly, even a twofold increase in CYP3A activity in the model, both in the gut wall and in the liver, led to an underestimation of $C_{\text{max}}$ and AUC. Assuming a 20% increase in $f_a$, hepatic CYP3A activity appears to increase 1.6-fold in pregnancy. Independent regulation of CYP3A activity in the liver and intestines is consistent with results of studies in mice, which showed that hepatic CYP3a activity increased 2.2- and 2.5-fold on gestational days 15 and 19, respectively, but that no change was observed in intestinal CYP3a activity or expression.

However, studies in the nonhuman primate Macaca nemestrina have not found increases in hepatic or intestinal CYP3A expression or midazolam clearance; the mechanism underlying the increase in hepatic CYP3A activity in humans is unknown.

Iterative analyses indicated that maintaining $V_{\text{max,GW}}$ at nonpregnancy values while increasing $V_{\text{max,HW}}$, $f_a$, and $k_e$ from the initial healthy volunteer parameter estimates resulted in the best fit of the observed pregnancy data. In order to achieve a better fit of the absorption profile, $k_e$ was estimated to increase to $2.5 \text{h}^{-1}$. As this increase in absorption rate was unexpected, we further interrogated the postpartum data. Changing $k_e$ in the healthy volunteer model from 1.17 to $2.5 \text{h}^{-1}$ appeared equally capable of predicting the postpartum data (see Supplementary Figure S3 online). Therefore the increase in $k_e$ appears to be attributable to the sample population, and is not an effect of pregnancy.

Validation with nifedipine

The pregnancy-induced changes proposed by the obstetric semi-mechanistic metabolism model were validated using nifedipine. Two-compartment pharmacokinetic parameters for nifedipine administered to healthy volunteers were obtained from the literature and adapted to fit the semi-mechanistic metabolism model by incorporation of in vitro $K_m$ and $V_{\text{max}}$ (see Supplementary Data online). Predictive checks of the model against published concentration–time profiles (Figure 4).
indicated that the healthy volunteer model described the data adequately. Changes in the volume of distribution, protein binding and hepatic CYP3A activity equivalent to those in the obstetrical midazolam model were applied. The model predictions of the mean nifedipine concentrations in subjects taking 20 mg nifedipine for preterm labor were within 15% of observed data. Several concentration values near the early points were overpredicted by the model, possibly because of the high inter-individual variation observed in absorption profiles.31

Obstetric PBPK models of pregnancy have typically focused on toxicokinetics and risk assessment.5 However, physiologic and drug-specific parameters can be incorporated into pharmacokinetics models to enhance understanding of drug metabolism in pregnancy. The eventual goal of such work is to develop a “virtual pregnant woman” model to predict the pharmacokinetics and effects of drugs in pregnancy. However, such models require the incorporation of gestational-age-dependent physiologic changes. While some of these physiologic changes can be estimated on the basis of gestational age or weight-based algorithms,32 quantitave knowledge of other changes is limited and more difficult to acquire. Further in vitro and in vivo studies of drug metabolism and transport during pregnancy are required to fully populate these virtual models. Future development of this model will incorporate gestational-age-related growth changes. Additionally, the effects of pregnancy on drug distribution and absorption, as well as other routes of elimination, will be incorporated into future models.

A limitation of this and other pharmacokinetic models is the difficulty in model validation. In practice, drug concentrations can be determined only in the central compartment (plasma). Pharmacokinetic models enable prediction of drug concentrations in other compartments, e.g., at the site of drug action or in the fetus. However, validation of these concentrations is unlikely to be carried out in humans. Fetal concentration values can be obtained noninvasively at birth from umbilical cord blood. However, these values are limited to a single time point after maternal dosing, and may not reflect drug exposures at earlier ages of gestation. To complicate matters, both mother and fetus are exposed to drugs taken by the mother, requiring consideration of both therapeutic effectiveness and the potential for toxicity.

In conclusion, we have shown that our midazolam semi-mechanistic metabolism model predicts midazolam pharmacokinetics in women in a postpartum setting. By incorporating physiologic changes associated with pregnancy, we show that increasing midazolam hepatic clearance 1.6-fold in the model leads to accurate estimates of the clearance of oral midazolam in pregnant women. This was confirmed using data from a second CYP3A substrate, nifedipine. However, further study would be required to fully validate the lack of change in intestinal clearance despite increased hepatic clearance. For example, a pharmacokinetics study involving semi-simultaneous intravenous and oral administration of a probe drug would be informative. The application of this model to substrates metabolized by other enzymes will allow us to better understand the changes in drug pharmacokinetics that are associated with pregnancy. This model is a first step in the development of predictive models for individualized dosing in pregnancy.

METHODS

Semi-mechanistic metabolism midazolam pharmacokinetic model. The semi-mechanistic metabolism pharmacokinetic model for midazolam in nonpregnant healthy subjects has been reported previously.7–9 For the obstetric model, two additional compartments were added to represent the placenta and fetus (Figure 1).

Elimination of midazolam occurs in the maternal gastrointestinal tract, liver, and kidney. In addition, the placenta and fetal liver have drug metabolizing capabilities. However, placental activity of CYP3A isoforms is minimal,24–27 and no evidence exists to indicate that midazolam is metabolized by the placenta. Therefore the placenta was not considered an organ of elimination in our model.

Maternal hepatic metabolism occurs through CYP3A-mediated and other enzymatic clearance pathways, e.g., glucuronidation. The CYP3A- and non-CYP3A-mediated intrinsic clearances of midazolam in the liver are estimated as:

$$\text{CL}_{\text{mx,3A}} = \frac{V_{\text{max,3A}}}{K_m + \mu_t \times C_H}$$

(1)

$$\text{CL}_{\text{nl,non3A}} = \frac{V_{\text{max,non3A}}}{K_m + \mu_t \times C_H}$$

(2)

where $V_{\text{max,3A}}$ and $V_{\text{max,non3A}}$ are the maximum velocity of metabolism by CYP3A and non-CYP3A mechanisms, $K_m$ is the Michaelis–Menten constant, $\mu_t$ is the unbound fraction of midazolam, and $C_H$ is the hepatic drug concentration.

Intrinsic clearance of midazolam within the gut wall (CL$_{\text{m,GW}}$) is assumed to be entirely by CYP3A; therefore,

$$\text{CL}_{\text{m,GW}} = \frac{V_{\text{max,3A}}}{K_m + C_{GW}}$$

(3)

where $V_{\text{max,3A}}$ is the maximum velocity of metabolism by CYP3A in the gut wall. The $K_m$ value for the gut wall is assumed to be equivalent to hepatic $K_m$.

The fetal liver primarily expresses CYP3A7. The metabolism of midazolam in the fetal liver, as in the adult liver, can be estimated by scaling up in vitro $V_{\text{max}}$ and $K_m$ values to estimate $V_{\text{max}}$ using Equation (4):33

$$V_{\text{max,Fet}} = V_{\text{max,3A7}} \times \text{ISEF} \times \text{CYP3A7 abundance} \times \text{MPPGL} \times \text{Liver weight}$$

(4)

where $V_{\text{max,Fet}}$ is the maximal reaction velocity in the fetal liver, $V_{\text{max,3A7}}$ is the maximal velocity determined in rCYP3A7 in vitro, ISEF is an intersystem extrapolation factor,34 CYP3A7 abundance is the amount of CYP3A7 enzyme per mg microsomal protein, and MPPGL is the amount of microsomal protein in mg per gram of liver. Williams et al. reported the in vitro $V_{\text{max}}$ and $K_m$ values of midazolam hydroxylation by recombinant CYP3A7 as 4 nmol/min/mg and 114 µmol/l, respectively.13 It is estimated that fetal liver microsomes contain 0.3 nmol CYP450 protein per mg.14 Based on ICRP data, the fetal liver weighs 130 g at 38 weeks gestation.12 MPPGL is estimated to be 26 mg/g.35 In the absence of data, ISEF was assumed to be 1. Therefore, $V_{\text{max,Fet}}$ is estimated as 88 mg/h.
Volumes of distribution established from compartmental pharmacokinetic analyses are used to estimate the volumes of the central and peripheral compartments. Liver, portal vein, gut, placenta, and fetal volumes were based on reported physiologic volume estimates, and these volumes are subtracted from the central distribution compartment. During pregnancy, women gain 12.5 kg of body weight on average. In the semi-mechanistic metabolism midazolam model, the portion of weight gain not accounted for by the fetus and placenta is divided between the central and peripheral compartments. The assumption is that extracellular fluid and blood volume reside in the central compartment, and that changes in other tissues and fat stores are a component of the peripheral compartment.

While total cardiac output increases in pregnancy, the value of $Q_h$ is assumed to be similar to that in the nonpregnant state, and is calculated as an allometric expression of total body weight:

$$Q_h = 3.75 \times \text{(body weight)}^{0.75}$$  \hspace{1cm} (5)

Hepatic artery flow ($Q_{ha}$) and portal venous blood flow ($Q_{pv}$) represent 25 and 75% of $Q_h$, respectively. Placental ($Q_{plac}$) and umbilical venous ($Q_{uv}$) blood flows were estimated at 30 weeks of gestational age.

Calibration data. Hebert et al. determined maternal plasma midazolam concentrations after a single 2 mg oral dose in women at 28–32 weeks of gestation. The study was repeated in the women at least 6 weeks postpartum. Individual plasma concentration–time profiles of these subjects were compared with the predicted concentration–time profiles for 500 individuals.

Sensitivity analysis. Sensitivity analysis was conducted to examine the effects of $V_{max,HA}$, $V_{max,GIF}$, $Q_h$, $V_P$, and fetal metabolism ($V_{max,fet}$) on the model. Starting from the initial model, each parameter was individually increased and decreased twofold, except for $V_{max,fet}$ which was reduced to 0 and increased 20-fold (Table 2).

Parameter optimization. Based on results of the sensitivity analysis, individual parameters or subsets of them were manually adjusted without taking interindividual variability into account, and holding all other parameters constant. Predicted concentrations were compared with the mean concentration–time curve data reported by Hebert et al. The optimal model was chosen based on visual inspection of the concentration vs. time plot and minimization of the residual sum of squares.

Nifedipine semi-mechanistic metabolism model. A healthy volunteer model and an obstetric semi-mechanistic pharmacokinetic model were constructed for another CYP3A substrate, nifedipine, using the same model structure as for midazolam. Central and peripheral volumes of distribution and $k_e$ were determined from published two-compartment analyses of nifedipine pharmacokinetics in healthy volunteers (Table 1). Nifedipine plasma concentrations in healthy volunteers after oral administration of 10 mg immediate-release capsules were extracted from mean concentration values reported in eight different studies involving healthy volunteers, using Grab-It Graph Digitizer (Datatrend Software, Raleigh, NC). In vitro $V_{max}$ and $K_m$ values of nifedipine in human liver microsomes were obtained from published studies (see Supplementary Data online). All other physiologic parameters, i.e., blood flows and physiologic organ volumes, were identical to the midazolam healthy volunteer semi-mechanistic metabolism model.

Nifedipine obstetric semi-mechanistic metabolism model. The pregnancy-associated changes in CYP3A activity, volume, and plasma protein binding identified in the midazolam semi-mechanistic metabolism obstetric pharmacokinetic model were applied to the corresponding model for nifedipine. Given that protein binding of midazolam and nifedipine are similar, changes in $f_a$ and central and peripheral volumes of distribution were applied as per the final midazolam model. Hepatic $V_{max}$ was increased 1.6-fold to account for increased CYP3A activity in pregnancy.

Nifedipine validation data. Predicted concentration–time curves of nifedipine after 20 mg oral dosing to pregnant women were compared to data obtained as part of the Under-studied Drugs in Pregnancy protocol conducted by the Obstetric-Fetal Pharmacology Research Unit network. The study examined nifedipine pharmacokinetics in 20 women (24–36 weeks gestation) who were receiving 10–20 mg immediate-release nifedipine every 4–8 h for preterm labor, as clinically indicated. Given that the majority of women were taking 20 mg every 6 h, the 10 mg doses were normalized to 20 mg for visualization and comparison. The study was approved by the institutional review board at each study site (Georgetown University, University of Pittsburgh, University of Texas Medical Branch-Galveston, and University of Washington), and written informed consent was obtained from all the participants.

Software and model analysis. All simulations were performed in R v 2.13.1 using the odesolve package. Noncompartmental analysis was performed using the PK package to obtain $AUC_{0-\infty}$ (midazolam) or $AUC_{0-t}$ (nifedipine). The example code is provided as online supplementary information (see Supplementary Data online). Predictions were compared with observed data using visual predictive checks and calculation of percentage error [(predicted – observed) / observed] and residual sum of squares.

Acknowledgments. This project was supported by grants P50HD04444, U10HD063094-01, 5U10HD047892, 5U10HD047890, 2U10HD04789107, and 1U10HD057753 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, and the National Institute of Health/National Center for Research Resources grants M01RR00037, UL1RR025014, and UL1RR031975. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.

Author Contributions. S.K.Q. wrote the manuscript. S.K.Q., M.F.H., D.M.H., S.C., J.G.U., and S.N.C. performed the research. S.K.Q. and A.N.M. analyzed the data. S.K.Q. contributed new reagents/analytical tools.

Conflict of Interest. The authors declared no conflict of interest.
Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

Physiologic changes in pregnancy, including changes in body composition and metabolic enzyme activity, can greatly affect drug pharmacokinetics, and thereby effectiveness and safety of drugs. Physiology-based pharmacokinetic models have traditionally been applied in fetal toxicology studies. However, such models are also capable of predicting therapeutic activity.

WHAT QUESTION DID THIS STUDY ADDRESS?

The aim of this study was to develop a semi-mechanistic metabolism model for CYP3A substrates in pregnancy. This model can help identify mechanistic changes responsible for the observed increased clearance of CYP3A substrates in pregnancy.

WHAT THIS STUDY ADDS TO OUR KNOWLEDGE

Using our model for CYP3A substrates in pregnancy, we are able to identify potential mechanisms for the pregnancy-associated changes in midazolam and nifedipine pharmacokinetics. Assuming a 20% increase in \( f_{\text{in}} \), the model indicates that hepatic, but not intestinal, metabolism by CYP3A increases 1.6-fold during pregnancy.

HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY AND THERAPEUTICS

This study supports the use of pharmacometric modeling to identify mechanisms of pharmacokinetic changes in pregnancy and provides a framework for future obstetric pharmacokinetic models.

1. Daw, J.R., Hanley, G.E., Greyson, D.L., & Morgan, S.G. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemid. Drug Saf. 20, 895–902 (2011).
2. McCullough, L.B., Coverdale, J.H. & Chervenak, F.A. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am. J. Obstet. Gynecol. 193, 301–307 (2005).
3. Lyerly, A.D., Little, M.O. & Faden, R. The second wave: Toward responsible inclusion of women in research. Clin. Pharmacol. Ther. 67, 408–414 (1999).
4. Zhao, P. Semiphysiologically based pharmacokinetic modeling: A model of predicting therapeutic activity. Br. J. Clin. Pharmacol. 62, 408–418 (2006).
5. Tracy, T.S., Venkataramanan, R., Glover, D.D. & Caritis, S.N.; National Institute for Child Health and Human Development of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am. J. Obstet. Gynecol. 192, 633–639 (2005).
6. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 32, 5–265 (2002).
7. Williams, J.A. et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 30, 883–891 (2002).
8. Shimada, T. et al. Characterization of micromolar cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24, 515–522 (1996).
9. Kleinbloesem, C.H., van Brummelen, P., von der Linde, J.A., Voogd, P.J. & Breimer, D.D. Nifedipine: kinetics and dynamics in healthy subjects. Clin. Pharmacol. Ther. 35, 742–749 (1984).
10. Raamsch, K.D. & Sommer, J. Pharmacokinetics and metabolism of nifedipine. Hypertension 5, I18–I24 (1983).
11. Haas, D.M. et al.; for the Obstetric-Fetal Pharmacology Research Units Network. Nifedipine pharmacokinetics are influenced by CYP2D6 genotype when used as a preterm tocolytic. Am. J. Perinatol. 29, e379–e386 (2012).
12. Schmiedlin-Ren, P., Thummel, K.E., Fisher, J.M., Painé, M.F., Lown, K.S., & Watkins, P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51, 741–754 (1997).
13. Kim, R.B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmacol. Res. 18, 408–414 (1999).
14. Gashua, L., Abduljallil, K., Jamel, M., Johnson, T.N. & Rostami-Hodjegan, A. A Pregnancy Physiologically-Based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4 and CYP2D6. Br. J. Clin. Pharmacol. (2012); e-pub ahead of print 22 June 2012.
15. Andrews, J. et al. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 32, 937–947 (2002).
16. Paré, P., Ceekevoi, M. & Staud, F. Variation of drug kinetics in pregnancy. Curr. Drug Metab. 10, 520–529 (2009).
17. Bacq, Y. et al. Liver function tests in normal pregnancy: a prospective study of 103 pregnant women and 103 matched controls. Hepatology 23, 1030–1034 (1996).
18. Schuetz, J.D., Kauma, S. & Guzelter, P.S. Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta. J. Clin. Invest. 92, 1018–1024 (1993).
19. Hakkola, J. et al. Detection of cytochrome P450 gene expression in human placenta in first trimester of pregnancy. Biochem. Pharmacol. 52, 379–383 (1996).
20. Hakkola, J. et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol. 51, 403–411 (1996).
21. Matsuoka, K., Motsumura, T., Takeda, Y., Kakei, M., Ohira, S. & Omori, S. Cytochrome P450 3A4 gene expression and testosterone 6 beta-hydroxylase activity in human fetal membranes and placenta at full term. Biol. Pharm. Bull. 33, 249–254 (2010).
22. Stevens, J.C. et al. Developmental expression of the major human hepatic CYP3A enzymes. J. Pharmacol. Exp. Ther. 307, 573–582 (2003).
23. Zhang, H. et al. Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-pregnant human primate, Macaca nemestrina. J. Pharmacol. Exp. Ther. 330, 586–595 (2009).
24. Nader, A.M., Carlits, S.N., Hebert, M.F., Clark, S.M., Flockhart, D.A. & Quinney, S.K. Component pharmacokinetics of immediate release nifedipine in pregnancy: variability in absorption. Clin. Pharmacol. Ther. 91, 106–109 (2012).
25. Young, J.F., Branham, W.S., Sheehan, D.M., Baker, M.E., Wosilait, W.D. & Luecke, R.H. Physiological “constants” for PBPK models for pregnancy. J. Toxicol. Environ. Health. 52, 385–401 (1997).
26. Hwang, E.I., Rowland Yeo, K., Proctor, N.J., Tucker, G.T. & Rostami-Hodjegan, A. Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica. 36, 473–497 (2006).
27. Proctor, N.J., Tucker, G.T. & Rostami-Hodjegan, A. Predicting drug clearance from recently updated CYPs: intersystem extrapolation factors. Xenobiotica. 34, 151–178 (2004).
28. Melkonian, O., Kaltiö, E.H., Larmi, T.K. & Kärki, N.T. Comparison of activities of drug-metabolizing enzymes in human fetal and adult livers. Clin. Pharmacol. Ther. 14, 840–846 (1973).
29. Wosilait, W.D., Luecke, R.H. & Young, J.F. A mathematical analysis of human embryonic and fetal growth data. Growth. Dev. Aging 56, 249–257 (1992).
30. Brown, B.P., Delp, M.D., Lindsett, S.L., Romberg, I.R. & Bellis, R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407–484 (1997).
31. Lees, C., Albajes, G., Deane, C., Parra, M. & Nicolades, K.H. Assessment of umbilical arterial and venous flow using color Doppler. Ultrasound Obstet. Gynecol. 14, 250–255 (1999).
43. Fuhr, U., Beckmann-Knoop, S., Jetter, A., Lück, H. & Mengs, U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med. 73, 1429–1435 (2007).

44. Wang, X.D. et al. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852, 534–544 (2007).

45. Chien, S.C., Uang, Y.S., Lin, H.Y. & Hsu, K.Y. Pharmacokinetics of nifedipine in Taiwanese. Biopharm. Drug Dispos. 25, 77–84 (2004).

46. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria R Foundation for Statistical Computing, 2011.

47. Jaki, T. & Wolfsegger, M.J. Estimation of pharmacokinetic parameters with the R package PK. Pharmaceutical Statistics 10, 284–288 (2011).

Supplementary Information accompanies this paper on the CPT: Pharmacometrics & Systems Pharmacology website (http://www.nature.com/psp)